RBC Europe’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

RBC Europe’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-130	Closed	-$112	–	1107
2019 Q4	$112	Hold	130	–	–	﹤0.01%	1032
2019 Q3	$73	Hold	130	–	–	﹤0.01%	1034
2019 Q2	$68	Hold	130	–	–	﹤0.01%	1052
2019 Q1	$59	Hold	130	–	–	﹤0.01%	1069
2018 Q4	$62	Hold	130	–	–	﹤0.01%	1077
2018 Q3	$69	Hold	130	–	–	﹤0.01%	1117
2018 Q2	$65	Hold	130	–	–	﹤0.01%	1129
2018 Q1	$55	Hold	130	–	–	﹤0.01%	1115
2017 Q4	$49	Hold	130	–	–	﹤0.01%	1126
2017 Q3	$47	Buy	+130	New	+$48	﹤0.01%	1127

RBC Europe's GCVRZ Position: Q1 2020 in Review

RBC Europe sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 130 shares — an estimated $112 sold.

RBC Europe first reported a position in GCVRZ in Q3 2017 and held it in 10 quarters. The position peaked at $112 in Q4 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.

RBC Europe reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
RBC Europe sold 130 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $112.
RBC Europe first reported a position in Sanofi Contingent Value Rights in Q3 2017 and held it in 10 quarters.
RBC Europe's Sanofi Contingent Value Rights position peaked at $112 in Q4 2019.
2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.

Based on RBC Europe's 13F filing for Q1 2020, filed 9 Nov 2023.